<DOC>
	<DOCNO>NCT01304511</DOCNO>
	<brief_summary>The purpose post-marketing surveillance identify problem question regard safety efficacy Orgalutran ( Ganirelix ) ® use prevention premature luteinizing hormone ( LH ) surge woman undergo controlled ovarian hyperstimulation ( COH ) assist reproduction technique ( ART ) .</brief_summary>
	<brief_title>Post-Marketing Surveillance Safety Efficacy Orgalutran ( Ganirelix ) ®</brief_title>
	<detailed_description />
	<mesh_term>Ganirelix</mesh_term>
	<criteria>Must undergo COH ART Hypersensitivity active substance excipients Hypersensitivity gonadotropinreleasing hormone ( GnRH ) GnRH analogue Moderate severe impairment renal hepatic function Pregnancy lactation</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>